BTK Inhibitor Rilzabrutinib Shows Efficacy in Immune Thrombocytopenia
Preliminary data from a phase 1/2 trial indicate that Principia Biopharma’s BTK inhibitor Rilzabrutinib could treat immune thrombocytopenia.
Autoimmune Disease
Researchers Profile Immune Cells Implicated in Neurodegenerative Diseases
The team of Dr. Katerina Akassoglou at Gladstone Institutes and UCSF studied the gene signature of pathogenic innate immune cells in the CNS.
JAK1 Inhibitor Filgotinib Shows Efficacy in Treatment of Psoriatic Arthritis
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Dupilumab for Eosinophilic Esophagitis: “Pivotal Data” in Phase 3 Trial
Dupixent (dupilumab), developed by Regeneron and Sanofi, has shown “significant efficacy” for Eosinophilic Esophagitis in a phase 3 trial.
Takeda’s Entyvio SC Approved in Europe as Maintenance Therapy for UC and CD
The European Commission approved subcutaneous Entyvio as a maintenance therapy for adults with Ulcerative Colitis or Crohn’s Disease.
Navidea: Positive Data in Phase 2B Trial of Tc99m Tilmanocept Imaging in RA
Navidea Biopharmaceuticals’ phase 2B NAV3-31 clinical trial is evaluating Tc99m Tilmanocept Planar Imaging in rheumatoid arthritis patients.
Gilead: Positive Phase 2b/3 Trial Data of Filgotinib for Ulcerative Colitis
Gilead JAK1 inhibitor Filgotinib 200 mg was shown to more effectively induce and maintain ulcerative colitis remission than a placebo.
COVID-19: Implications for Ulcerative Colitis and Crohn’s Disease Patients
A physician, Dr. Giovanni Monteleone MD PhD, outlines the implications of COVID-19 for Ulcerative Colitis and Crohn’s Disease patients.
Regulatory T cells control fibroblast activation in skin to suppress the pathogenesis of tissue fibrosis
The activity and function of regulatory T cells (Tregs) largely depends on the tissue in which they reside. Recent research has identified that Tregs in the skin are primed to control the pathogenesis of tissue fibrosis by expressing a unique transcriptional signature that supports the effective suppression of type 2 immune responses.
Liver X Receptor Supporting Blood Brain Barrier Offers Insight into Multiple Sclerosis Treatment
Knocking out a form of the liver X receptor, a protein involved in the regulation of gene expression, was found to promote inflammation and the loss of protective proteins in the blood-brain barrier, suggesting that the upregulation of these receptors could be considered as an approach to Multiple Sclerosis treatment.